Hosted by the Commercialisation Team based in the Division of Research, Enterprise and Innovation
beLAB1407 is a partnership with Evotec and Bristol Myers Squibb to identify exciting and novel disease modifying therapeutic targets and platforms with the goal to develop these to new spinout companies or licensing opportunities. It offers a unique opportunity for interested academics to access translational funding, experience industrial pharmaceutical drug discovery processes and to develop innovative ideas at first hand. For successful projects, we also offer the opportunity for those with an entrepreneurial interest to be involved in shaping the future of the spinout.
beLAB1407 provides funding, technology platforms and mentoring to achieve pre-clinical proof of concept for novel therapeutic targets and technologies. Up to £1.25 million per project is available to support collaborative academic/ industry development projects with an interest in oncology, neuroscience and inflammation.
beLAB1407 is interested in targets and platforms to yield first-in-class therapeutics; projects may include target validation, screening and optimisation of previously identified chemical matter / platforms.
If you think you may have a suitable project please contact Harriet or Olivia in the Research Commercialisation Team to talk through the project fit with the Evotec Entrepreneur in Residence and to book in for one-to-one sessions. Please note that there will only be time for a limited number of one-to-one sessions on the day for academics to meet directly with beLAB1407 and these will be allocated on a first come first serve basis following consultation with the relevant Commercialisation Manager to ensure project fit.
Please contact:
Harriet.Bray@bristol.ac.uk for all Faculty of Life Sciences projects
Olivia.Champion@bristol.ac.uk for all Faculty of Health Sciences projects
Register for your free place - please note places are strictly limited, and lunch will be provided.